Oral presentation
Open Access
Volume 10 Supplement 1
IRSSD 2014 Meeting Abstracts
Longitudinal performance of polycaprolactone-based scaffold plus recombinant human morphogenetic protein-2 (rhBMP-2) in large preclinical animal model: 6- versus 12 months
Scoliosis201510(Suppl 1):O58
https://doi.org/10.1186/1748-7161-10-S1-O58
© Yong et al; licensee BioMed Central Ltd. 2015
Published: 19 January 2015
Objectives
There is strong current interest in the use of biodegradable scaffolds in combination with bone growth factors as a valuable alternative to the current gold standard autograft in spinal fusion surgery (Yong et al. 2013). Here we report on 6- vs 12- month data set evaluating the longitudinal performance of a CaP coated polycaprolactone (PCL) scaffold loaded with recombinant human bone morphogenetic protein-2 (rhBMP-2) as a bone graft substitute within a preclinical ovine thoracic spine.
Material and methods
Twelve sheep underwent a 3-level (T6/7, T8/9 and T10/11) discectomy with randomly allocated implantation of a different graft substitute at each of the three levels; (i) calcium phosphate (CaP) coated polycaprolactone based scaffold plus 0.54mcg rhBMP-2, (ii) CaP coated PCL- based scaffold alone or (iii) autograft (mulched rib head). Fusion assessments were performed via high resolution clinical computed tomography and histological evaluation were undertaken at six (n=6) and twelve (n=6) months post-surgery using the Sucato grading system (Sucato et al. 2004).
Results
The computed tomography fusion grades of the 6- and 12- months in the rhBMP-2 plus PCL- based scaffold group were 1.9 and 2.1 respectively, in the autograft group 1.9 and 1.3 respectively, and in the scaffold alone group 0.9 and 1.17 respectively. There were no statistically significant differences in the fusion scores between 6- and 12- month for the rhBMP plus PCL- based scaffold or PCL - based scaffold alone group however there was a significant reduction in scores in the autograft group. These scores were seen to correlate with histological evaluations of the respective groups.
Conclusions
The results of this study demonstrate the efficacy of scaffold-based delivery of rhBMP-2 in promoting higher fusion grades at 6- and 12- months in comparison to the scaffold alone or autograft group within the same time frame. Fusion grades achieved at six months using PCL+rhBMP-2 are not significantly increased at twelve months post surgery.
Authors’ Affiliations
(1)
QUT/Mater Paediatric Spine Research Group, Queensland University of Technology, Mater Misericordiae Health Services
(2)
Institute of Health and Biomedical Innovation, Queensland University of Technology
References
- Sucato DJ, Hedequist D, Zhang H, Pierce W, O'Brien SE, Welch RD: Recombinant Human Bone Morphogenetic Protein - 2 Enhances Anterior Spinal Fusion in a Thoracoscopically Instrumented Animal Model. The Journal of Bone and Joint Surgery American Volume. 2004, 86-A (4): 752-762.PubMedGoogle Scholar
- Yong MRNO, Saifzadeh S, Askin GN, Labrom RD, Hutmacher DW, Adam CJ: Biological Performance of a Polycaprolactone -based Scaffold plus Recombinant Human Morphogenetic Protein - 2 (rhBMP-2) in an Ovine Thoracic Interbody Fusion Model. European Spine Journal. 2013, DOI 10.1007/s00586-013-2085-xGoogle Scholar
Copyright
© Yong et al; licensee BioMed Central Ltd. 2015
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
